Amygdala Advances ANS-858 After FDA IND Clearance
PALO ALTO, Calif., August 18, 2026 Amygdala Neurosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
FDA IND Clearance
Advertisement
Graviton Bioscience Gains FDA IND Clearance for GV101
New York, New York, August,11, 2026 Graviton Bioscience Corporation, a clinical-stage biotechnology company developing selective ROCK2 inhibitors, has announced...
Ascletis Begins U.S. Phase I Trials of Monthly Obesity Drugs
Hong Kong, China, August 10, 2026 Ascletis Pharma Inc. has announced the initiation of two Phase I clinical studies...
Ractigen’s RAG-1C Wins FDA IND Clearance for PVR
NANTONG, China, July 31, 2026 Ractigen Therapeutics has received U.S. Food and Drug Administration (FDA) clearance of its Investigational...
Iksuda Therapeutics Secures FDA IND Clearance for IKS04
Newcastle, UK, July 30, 2026 Iksuda Therapeutics has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)...
Advertisements
CoRegen Wins FDA IND Clearance for CRG-150
HOUSTON, July 7, 2026 CoRegen, Inc. has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance...
Merck’s KEYTRUDA Tops Chemo in dMMR Endometrial Cancer
RAHWAY, N.J., July 15, 2026 Merck has announced that its blockbuster PD-1 inhibitor KEYTRUDA® (pembrolizumab) achieved the primary endpoint...
Kelun-Biotech Advances SKB575 with China IND Approval
CHENGDU, China, July 15, 2026 Kelun-Biotech and Harbour BioMed have announced that China’s National Medical Products Administration (NMPA) has...
MAXONA Wins FDA IND Clearance for MAX-001 Phase 2 Trial
MALVERN, Pa., July 15, 2026 MAXONA Pharmaceuticals has received U.S. FDA Investigational New Drug (IND) clearance to initiate a...
Akeso Opens U.S. Phase II Trial for PD-1/CTLA-4 Bispecific
HONG KONG, July 14, 2026 Akeso, Inc. has announced the launch of a Phase II clinical trial in the...
Advertisement
